KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBT (2017 - 2025)

Biomarin Pharmaceutical's EBT history spans 16 years, with the latest figure at -$27.2 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 116.01% year-over-year to -$27.2 million, compared with a TTM value of $482.5 million through Dec 2025, down 10.94%, and an annual FY2025 reading of $482.5 million, down 10.94% over the prior year.
  • EBT for Q4 2025 was -$27.2 million at Biomarin Pharmaceutical, down from -$26.3 million in the prior quarter.
  • The five-year high for EBT was $297.9 million in Q2 2025, with the low at -$66.6 million in Q4 2021.
  • Average EBT over 5 years is $64.4 million, with a median of $38.3 million recorded in 2022.
  • Year-over-year, EBT skyrocketed 2288.5% in 2023 and then tumbled 119.58% in 2025.
  • Tracing BMRN's EBT over 5 years: stood at -$66.6 million in 2021, then surged by 73.63% to -$17.6 million in 2022, then surged by 210.08% to $19.3 million in 2023, then surged by 777.73% to $169.6 million in 2024, then crashed by 116.01% to -$27.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBT are -$27.2 million (Q4 2025), -$26.3 million (Q3 2025), and $297.9 million (Q2 2025).